What Happened

The FDA approved Biofrontera's Ameluz (ALA hydrochloride) topical gel, 10%, used with the BF-RhodoLED lamp, for treating superficial basal cell carcinoma (BCC) in adults. This marks the first photodynamic therapy (PDT) drug approved in the US for skin cancer. Ameluz had been approved for actinic keratoses since 1999.

Who Is Affected

Biofrontera, a German public biotech company, is the protagonist. The approval affects dermatologists and patients with superficial BCC, particularly those who cannot or prefer not to undergo surgery. Key opinion leaders from Memorial Sloan Kettering Cancer Center and Dartmouth Hitchcock Medical Center commented on the approval.

Market Impact

The approval is critical for securing insurance coverage and gives the treatment "even more substantiated validity," according to Anthony Rossi, MD, of Memorial Sloan Kettering. It opens a new US market for Biofrontera beyond actinic keratoses.

• Expanded label: First US PDT approval for skin cancer, creating a new commercial opportunity.
• Reimbursement: FDA approval is key to insurance coverage, driving market access.
• Patient population: Benefits patients with multiple BCCs (e.g., Gorlin syndrome, immunocompromised) and those avoiding surgery.

What to Watch

Monitor Biofrontera's US commercial launch and market access strategy. The approval may drive adoption in dermatology practices, especially for patients with superficial BCC in cosmetically sensitive areas. Watch for payer coverage decisions and competitive responses from surgical alternatives.

Related coverage

• FDA Grants 510(k) Clearance to Click Therapeutics' Motivista for Schizophrenia
• FDA approves AbbVie's Parkinson's drug Juvmo (tavapadon) developed from UVA research
• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• Mirum Pharmaceuticals Wins FDA Approval for Atebrioz for Rare Bone Disorder FOP